TY - JOUR

T1 - Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli

AU - Comuth, Willemijn

AU - Münster, Anna-Marie Bloch

AU - Kümler, Thomas

AU - Hellfritzsch, Maja

AU - Larsen, Sanne Bøjet

AU - Hansen, Morten Lock

AU - Grove, Erik Lerkevang

PY - 2019

Y1 - 2019

N2 - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.

AB - If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients' preferences should be considered.

KW - Anticoagulants/therapeutic use

KW - Humans

KW - Pulmonary Embolism/drug therapy

KW - Recurrence

KW - Risk Factors

KW - Time Factors

KW - Venous Thromboembolism/complications

M3 - Tidsskriftartikel

C2 - 30777593

VL - 181

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

M1 - V05180345

ER -